Papillary renal cell carcinoma
MONDO:0017884A rare subtype of renal cell carcinoma, arising from the renal tubular epithelium and showing a papillary growth pattern, which typically manifests with hematuria, flank pain, palpable abdominal mass or nonspecific symptoms, such as fatigue, weight loss or fever. Symptoms related to metastatic spread, such as bone pain or persistent cough, are frequently associated since early diagnosis is not common. It is typically multifocal, bilateral, and in most cases sporadic, although different hereditary syndromes, such as Hereditary leiomyoma renal cell carcinoma, Birt-Hogg-DubC) syndrome and Tuberous sclerosis, may predispose to the development of papillary renal cell carcinoma.
Also known as: HPRCC, chromophil carcinoma of kidney, chromophil carcinoma of the kidney, chromophil renal cell carcinoma, papillary (chromophil) renal cell carcinoma, papillary renal cell adenocarcinoma, papillary renal cell cancer, papillary renal cell carcinoma
2804 clinical trials for this condition and its sub-types, 26 tagged with Papillary renal cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Papillary renal cell carcinoma
-
Experimental immune cell therapy targets Hard-to-Treat cancers
Disease control Stopped earlyThis early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…
Phase 1 • Sponsor: Instil Bio • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cancer drug PRO1160 tested in advanced cancers – trial ends early
Disease control Stopped earlyThis study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC